Phase II Study of 13-cis-Retinoic Acid plus Interferon-α2a in Heavily Pretreated Squamous Carcinoma of the Cervix
| Autor: | Glenn J. Shamdas, Earl A. Surwit, Kenneth D. Hatch, Scott M. Lippman, David S. Alberts, Joel M. Childers, Lora Inclan, Manuel R. Modiano, Alton V. Hallum |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Uterine Cervical Neoplasms Phases of clinical research Alpha interferon Interferon alpha-2 Gastroenterology Internal medicine medicine Carcinoma Humans Isotretinoin Cervix Interferon alfa Aged Chemotherapy business.industry Interferon-alpha Obstetrics and Gynecology Middle Aged medicine.disease Combined Modality Therapy Recombinant Proteins Squamous carcinoma medicine.anatomical_structure Endocrinology Oncology Carcinoma Squamous Cell Female business Progressive disease medicine.drug |
| Zdroj: | Gynecologic Oncology. 56:382-386 |
| ISSN: | 0090-8258 |
| DOI: | 10.1006/gyno.1995.1067 |
| Popis: | The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-alpha 2a was given subcutaneously at a dose of 3 million units/m2/day. Thirteen of 14 patients enrolled in this study are evaluable for response and toxicity. There were no complete or partial responses. Ten patients had progressive disease and the remaining three had stable disease. Principle toxicities were fatigue, nausea, and vomiting. This regimen appears cross-resistant with radiotherapy and/or platinum-based cytotoxic therapy in heavily pretreated patients with squamous carcinoma of the cervix. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect